Goldman Sachs’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-28,200
Closed -$938K 5652
2020
Q2
$938K Buy
+28,200
New +$898K ﹤0.01% 3997
2018
Q1
Sell
-2,000
Closed -$28K 6552
2017
Q4
$28K Sell
2,000
-1,800
-47% -$24.3K ﹤0.01% 6063
2017
Q3
$70K Sell
3,800
-4,600
-55% -$76.9K ﹤0.01% 6177
2017
Q2
$142K Buy
8,400
+2,000
+31% +$30.4K ﹤0.01% 5974
2017
Q1
$85K Buy
6,400
+4,100
+178% +$64.2K ﹤0.01% 6124
2016
Q4
$35K Buy
2,300
+500
+28% +$6.6K ﹤0.01% 6486
2016
Q3
$21K Buy
1,800
+1,100
+157% +$12.9K ﹤0.01% 6742
2016
Q2
$8K Sell
700
-51,000
-99% -$526K ﹤0.01% 6891
2016
Q1
$478K Sell
51,700
-15,900
-24% -$171K ﹤0.01% 4780
2015
Q4
$1M Sell
67,600
-111,700
-62% -$1.87M ﹤0.01% 4293
2015
Q3
$2.94M Buy
179,300
+94,700
+112% +$1.94M ﹤0.01% 3397
2015
Q2
$1.93M Buy
84,600
+79,600
+1,592% +$1.59M ﹤0.01% 3862
2015
Q1
$76K Sell
5,000
-7,000
-58% -$90.9K ﹤0.01% 6549
2014
Q4
$144K Sell
12,000
-77,100
-87% -$881K ﹤0.01% 6387
2014
Q3
$1.01M Buy
89,100
+68,500
+333% +$781K ﹤0.01% 4604
2014
Q2
$249K Sell
20,600
-79,700
-79% -$941K ﹤0.01% 6026
2014
Q1
$1.17M Sell
100,300
-1,500
-1% -$25.4K ﹤0.01% 4516
2013
Q4
$1.8M Sell
101,800
-142,700
-58% -$2.4M ﹤0.01% 4187
2013
Q3
$3.52M Buy
244,500
+214,000
+702% +$3.28M ﹤0.01% 3332
2013
Q2
$459K Buy
+30,500
New +$403K ﹤0.01% 5012

Goldman Sachs's MNTA Position: Q4 2020 in Review

Goldman Sachs sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 1,610,731 shares — an estimated $84.5M sold.

Goldman Sachs first reported a position in MNTA in Q2 2013 and held it in 30 quarters. The position peaked at $84.5M in Q3 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.

  • Goldman Sachs reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Goldman Sachs sold 1,610,731 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $84.5M.
  • Goldman Sachs first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 30 quarters.
  • Goldman Sachs's Momenta Pharmaceuticals, Inc. position peaked at $84.5M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.

Based on Goldman Sachs's 13F filing for Q4 2020, filed 12 Feb 2021.